Maxime Meylan

3.4k total citations · 3 hit papers
24 papers, 1.4k citations indexed

About

Maxime Meylan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Maxime Meylan has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Immunology. Recurrent topics in Maxime Meylan's work include Cancer Immunotherapy and Biomarkers (14 papers), Renal cell carcinoma treatment (10 papers) and Immune Cell Function and Interaction (7 papers). Maxime Meylan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Renal cell carcinoma treatment (10 papers) and Immune Cell Function and Interaction (7 papers). Maxime Meylan collaborates with scholars based in France, Belgium and United States. Maxime Meylan's co-authors include Wolf H. Fridman, Catherine Sautès‐Fridman, Florent Petitprez, Cheng‐Ming Sun, Aurélien de Reyniès, Antoîne Italiano, Tom Wei‐Wu Chen, Lubka T. Roumenina, Guilhem Pupier and Anne Calvez and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Immunity.

In The Last Decade

Maxime Meylan

21 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

2020 401 citations Florent Petitprez, Maxime Meylan et al. Frontiers in Immunology profile →
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome

2022 379 citations Wolf H. Fridman, Maxime Meylan et al. Nature Reviews Clinical Oncology profile →
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle

2023 137 citations Wolf H. Fridman, Maxime Meylan et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maxime Meylan France	9	850	700	389	308	231	24	1.4k
Heather Metz United States	9	657 0.8×	694 1.0×	312 0.8×	372 1.2×	193 0.8×	16	1.4k
Aiqin Gao China	16	577 0.7×	669 1.0×	391 1.0×	208 0.7×	289 1.3×	38	1.3k
Gert Van den Eynden Belgium	17	861 1.0×	445 0.6×	400 1.0×	289 0.9×	381 1.6×	34	1.3k
John Lövrot Sweden	13	923 1.1×	466 0.7×	714 1.8×	220 0.7×	566 2.5×	21	1.6k
Guozhu Xie China	20	829 1.0×	616 0.9×	581 1.5×	192 0.6×	365 1.6×	33	1.6k
Rilan Bai China	13	567 0.7×	306 0.4×	240 0.6×	247 0.8×	171 0.7×	36	920
Sahar Mahmoud United Kingdom	6	1.4k 1.6×	1.1k 1.5×	313 0.8×	212 0.7×	278 1.2×	6	1.8k
Giorgia Maroni Italy	5	460 0.5×	667 1.0×	512 1.3×	141 0.5×	148 0.6×	7	1.1k
Lucia Festino Italy	18	880 1.0×	375 0.5×	368 0.9×	190 0.6×	109 0.5×	39	1.2k
И. Г. Козлов Russia	7	413 0.5×	258 0.4×	339 0.9×	276 0.9×	223 1.0×	43	852

Countries citing papers authored by Maxime Meylan

Since Specialization

Citations

This map shows the geographic impact of Maxime Meylan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxime Meylan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxime Meylan more than expected).

Fields of papers citing papers by Maxime Meylan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxime Meylan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxime Meylan. The network helps show where Maxime Meylan may publish in the future.

Co-authorship network of co-authors of Maxime Meylan

This figure shows the co-authorship network connecting the top 25 collaborators of Maxime Meylan. A scholar is included among the top collaborators of Maxime Meylan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxime Meylan. Maxime Meylan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russick, Jules, Carine Torset, Dan Sun, et al.. (2024). Tumor stage-driven disruption of NK cell maturation in human and murine tumors. iScience. 27(11). 111233–111233.

Rioux‐Leclercq, Nathalie, Maxime Meylan, Christophe Passot, et al.. (2023). Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 11(11). e006885–e006885. 8 indexed citations

Naigeon, Marie, Ronan Flippot, Cécile Dalban, et al.. (2023). 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study. Immuno-Oncology Technology. 20. 100643–100643. 1 indexed citations

Carril-Ajuria, Lucía, Marie Naigeon, Cécile Dalban, et al.. (2023). Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.. Journal of Clinical Oncology. 41(6_suppl). 724–724. 1 indexed citations

Fridman, Wolf H., Maxime Meylan, Guilhem Pupier, et al.. (2023). Tertiary lymphoid structures and B cells: An intratumoral immunity cycle. Immunity. 56(10). 2254–2269. 137 indexed citations breakdown →

Vano, Yann, Audrey Simonaggio, Mostefa Bennamoun, et al.. (2023). Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.. Journal of Clinical Oncology. 41(6_suppl). 607–607. 2 indexed citations

Meylan, Maxime, Catherine Sautès‐Fridman, & Wolf H. Fridman. (2022). Les structures lymphoïdes tertiaires génèrent et propagent des plasmocytes produisant des anticorps antitumoraux dans le cancer du rein. médecine/sciences. 38(6-7). 536–538. 2 indexed citations

Meylan, Maxime, Maria João Moreira, Antoine Bougoüin, et al.. (2022). 1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial. Annals of Oncology. 33. S1207–S1207. 2 indexed citations

Fridman, Wolf H., Maxime Meylan, Florent Petitprez, et al.. (2022). B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology. 19(7). 441–457. 379 indexed citations breakdown →

10.

Naigeon, Marie, Cécile Dalban, Aude Desnoyer, et al.. (2022). The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.. Journal of Clinical Oncology. 40(6_suppl). 379–379.

11.

Kinget, Lisa, Eduard Roussel, Diether Lambrechts, et al.. (2021). 689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC). Annals of Oncology. 32. S706–S706. 2 indexed citations

12.

Naigeon, Marie, Cécile Dalban, Aude Desnoyer, et al.. (2021). 687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab. Annals of Oncology. 32. S704–S705.

13.

Russick, Jules, Nathalie Josseaume, Maxime Meylan, et al.. (2021). Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology. 12. 701273–701273. 4 indexed citations

14.

Khouzam, Raefa Abou, R. Shyama Prasad Rao, Goutham Hassan Venkatesh, et al.. (2021). An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Frontiers in Immunology. 12. 680435–680435. 32 indexed citations

15.

Petitprez, Florent, Cheng‐Ming Sun, Maxime Meylan, et al.. (2020). The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine. 12(1). 86–86. 87 indexed citations

16.

Meylan, Maxime, Benoit Beuselinck, Cécile Dalban, et al.. (2020). 700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). Annals of Oncology. 31. S553–S553. 7 indexed citations

17.

Petitprez, Florent, Maxime Meylan, Aurélien de Reyniès, Catherine Sautès‐Fridman, & Wolf H. Fridman. (2020). The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology. 11. 784–784. 401 indexed citations breakdown →

18.

Meylan, Maxime, Florent Petitprez, Laetitia Lacroix, et al.. (2020). Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clinical Cancer Research. 26(16). 4381–4389. 76 indexed citations

19.

Sautès‐Fridman, Catherine, Johanna Verneau, Cheng‐Ming Sun, et al.. (2020). Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Seminars in Immunology. 48. 101406–101406. 57 indexed citations

20.

Meylan, Maxime, C. P. Henny, E Temler, E Jéquier, & J. P. Felber. (1987). Metabolic factors in the insulin resistance in human obesity. Metabolism. 36(3). 256–261. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact